Every Form 4 that Denali Therapeutics Inc. (DNLI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DNLI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNLI filings page.
Denali Therapeutics Inc. (DNLI) reported that Chief Medical Officer Peter Scott Chin sold 1,654 shares of common stock on September 4, 2026 at a weighted average price of $22.29 per share. The shares were sold to satisfy tax obligations related to settlement of previously vested restricted stock units, and he now holds 204,538 shares, including 142,845 unvested RSUs and 1,790 shares acquired under the ESPP on June 1, 2026. No Rule 10b5-1 trading plan is reported for this transaction.
Denali Therapeutics Inc. (DNLI) reported that director Nancy Thornberry sold common stock in two open-market or private transactions on September 2, 2026. She sold 10,824 shares at a weighted average price of $22.85 per share and 615 shares at a weighted average price of $23.74 per share. The filing states these sales were effected under a Rule 10b5-1 trading plan adopted June 3, 2026 and that her holdings include 6,408 unvested RSUs after the reported transactions.
Denali Therapeutics Inc. (DNLI) reported that its COFO and Secretary, Alexander O. Schuth, sold 2,768 shares of Common Stock on September 1, 2026 at $23.44 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. After this transaction, Schuth directly held 278,995 shares, including 135,475 unvested RSUs, and indirectly held 523,749 shares through The Schuth Family Trust, for which he serves as trustee.
Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a bona fide gift of 32,220 shares of Denali common stock on August 12, 2026. The in-kind charitable contribution was made to a donor advised fund from shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee. After the transactions, he reports 2,120,384 indirect shares and 296,833 direct shares, including 184,915 unvested RSUs.
Denali Therapeutics Inc. officer Alexander O. Schuth reported selling 2,857 shares of common stock on 2026-08-11 at $25.07 per share, with a footnote stating the shares were sold to satisfy tax obligations related to previously vested RSUs. Following this transaction, he directly holds 281,763 shares, including 135,475 unvested RSUs and 1,792 shares acquired under the ESPP on June 1, 2026, and indirectly holds 523,749 shares through The Schuth Family Trust, where he serves as trustee. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.
Denali Therapeutics Inc. director Jay T. Flatley reported new equity awards in the form of common stock and stock options. He received 6,408 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock, with 100% of the RSUs vesting on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting.
Flatley was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring on June 3, 2036. Following these grants, he holds 22,628 shares directly, including 6,408 unvested RSUs, and 336,313 shares indirectly through The Flatley Family Trust, for which he serves as trustee. The filing does not show any open-market purchases or sales.
Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.
He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.
Denali Therapeutics director Steve E. Krognes reported equity awards and updated holdings. He received 6,408 shares of common stock in the form of Restricted Stock Units, which will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual stockholder meeting. He was also granted stock options for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule and an expiration date in 2036. Following these grants, he holds 38,202 shares directly and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee.
Denali Therapeutics director David P. Schenkein reported new equity awards. He received 6,408 Restricted Stock Units, each representing a contingent right to one share of common stock. These RSUs vest in full on the earlier of one year from grant or the day before the next annual stockholder meeting.
He also received a stock option for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule. After these grants, he directly holds 21,665 common shares, and additional common shares are held indirectly through the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust.
Denali Therapeutics Inc. director Nancy Thornberry reported routine equity compensation awards. She received 6,408 Restricted Stock Units, each tied to one share of common stock, which will fully vest on the earlier of one year from grant or the day before the next annual stockholder meeting.
She was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, with the same vesting schedule and expiration in 2036. Following these awards, she directly holds 31,125 shares of common stock, including the unvested RSUs.
Denali Therapeutics director Timothy Van Hauwermeiren received new equity awards as part of his compensation. He was granted 6,408 shares of common stock in the form of Restricted Stock Units (RSUs), each representing a contingent right to one share of Denali common stock.
All of these RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual meeting of stockholders. After this grant, he holds 17,040 RSUs in total, which are all unvested. He was also granted options to purchase 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring in 2036.
Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.
Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Denali Therapeutics Inc. director Julian C. Baker received equity-based compensation linked to Baker Brothers funds. The filing reports a grant of 6,408 restricted stock units payable in Denali common stock and 19,226 non-qualified stock options exercisable into common stock at a strike price of $19.66 per share. Both the RSUs and options vest on the earlier of June 3, 2027 or the day prior to Denali’s next annual meeting after June 3, 2026, subject to his continued board service. The transactions are reported as indirect interests of 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP holding voting and dispositive power. Felix and Julian Baker, the adviser and its general partner all disclaim beneficial ownership beyond their indirect pecuniary interests.
Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a sale of common stock in a Form 4 filing. On January 6, 2026, he sold 35,198 shares of Denali common stock at $16.50 per share, and the filing explains that these shares were sold to satisfy tax obligations related to the settlement of previously vested restricted stock units (RSUs). Following this transaction, he directly beneficially owned 296,833 shares, which include 184,915 unvested RSUs. The filing also reports an additional 2,152,604 shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee.
Denali Therapeutics Inc. officer Alexander O. Schuth, the company’s COFO and Secretary, reported a sale of common stock. On 01/06/2026, he sold 17,218 shares of Denali common stock at $16.5 per share, with the filing stating that the sale was made to satisfy his tax obligations related to the settlement of previously vested restricted stock units (RSUs). After this transaction, he beneficially owned 282,828 shares directly, which the filing notes includes 141,100 unvested RSUs. The filing also reports 523,749 shares held indirectly through The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee.
Denali Therapeutics Inc. insiders affiliated with Baker Brothers reported large purchases of $0.01 prefunded warrants to buy the company’s common stock. On December 11, 2025, 667, L.P. acquired 190,523 prefunded warrants and Baker Brothers Life Sciences, L.P. acquired 2,095,191 prefunded warrants in a public offering at $17.49 per warrant. Each warrant is exercisable at any time on a 1-for-1 basis into common stock at an exercise price of $0.01 per share, with no expiration date.
These warrants can only be exercised to the extent the holders and their affiliates would beneficially own no more than 4.99% of Denali’s outstanding common stock, a cap that can be adjusted up to 19.99% with 61 days’ notice. After these transactions, 667, L.P. beneficially owned 2,335,469 prefunded warrants and Baker Brothers Life Sciences, L.P. beneficially owned 25,996,310 prefunded warrants. Julian C. Baker is a director of Denali, and other reporting persons are deemed directors by deputization through their board representation and advisory roles.
Denali Therapeutics (DNLI) filed a Form 4 for a director equity grant. On 11/04/2025, the director received 10,632 restricted stock units at $0 and was shown beneficially owning 10,632 common shares after the transaction, held directly.
The director was also granted a stock option for 31,897 shares at an exercise price of $14.92, expiring 11/04/2034. RSUs vest in four equal annual installments from the grant date, subject to service. Options vest 25% on November 4, 2026, with the remainder vesting monthly in equal 1/48 increments thereafter.